SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-09-09 | Open-market sell 10b5-1 | 23 | $8K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-09-08 | Open-market sell 10b5-1 | 46 | $17K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-08-21 | Open-market sell 10b5-1 | 77 | $29K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-08-20 | Open-market sell 10b5-1 | 77 | $31K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-08-19 | Open-market sell 10b5-1 | 77 | $30K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-08-18 | Open-market sell 10b5-1 | 77 | $30K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-08-17 | Open-market sell 10b5-1 | 77 | $30K |
| GUTHART GARY S | Director | 2026-08-11 | Open-market sell 10b5-1 | 10000 | $4.0M |
| Ladd Amy L | Director | 2026-08-11 | Open-market sell 10b5-1 | 72 | $28K |
| LOEB GARY | EVP & Chief Legal and Complian | 2026-08-10 | Open-market sell 10b5-1 | 400 | $152K |
| Ladd Amy L | Director | 2026-08-10 | Open-market sell 10b5-1 | 400 | $152K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-07-31 | Open-market sell 10b5-1 | 28 | $10K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-07-30 | Open-market sell 10b5-1 | 28 | $10K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-07-29 | Open-market sell 10b5-1 | 28 | $10K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-07-28 | Open-market sell 10b5-1 | 28 | $10K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-07-27 | Open-market sell 10b5-1 | 28 | $10K |
| Rosa David J. | Chief Executive Officer (CEO), Director | 2026-07-10 | Option exercise | 1910 | $0 |
| Rosa David J. | Chief Executive Officer (CEO), Director | 2026-07-10 | Tax withholding | 947 | $390K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-06-12 | Open-market sell 10b5-1 | 25 | $10K |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 2026-06-11 | Open-market sell 10b5-1 | 23 | $9K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regulatory risk has broadened materially across multiple jurisdictions and domains — EU MDR, EU AI Act, EU HTA, new U.S. state AI laws, and OBBBA-driven demand headwinds all escalated simultaneously, with no meaningful offsets. Chinese rare earth export controls add a concrete supply chain disruption vector, while expanded competitive threats and ESG litigation exposure compound the picture. The aggregate shift is a substantive worsening concentrated in regulatory compliance and operations, though no solvency or going-concern risk is present.
3 company-specific · 5 common-mode
New disclosure of Chinese rare earth export controls and licensing requirements creating concrete supply chain disruption risk with potential product export licensing obligations.
OUR RELIANCE ON SOLE- AND SINGLE-SOURCED SUPPLIERS AND ABILITY TO PURCHASE AT ACCEPTABLE PRICES A SUFFICIENT SUPPLY OF MATERIALS COULD HARM OUR ABILITY TO MEET PRODUCT DEMAND IN A TIMELY MANNER OR…
New substantial disclosure of EU MDR compliance requirements and CE marking obligations. Adds material regulatory risk for EU market access and product commercialization.
RISKS RELATING TO OUR REGULATORY ENVIRONMENT COMPLYING WITH FDA AND FOREIGN REGULATIONS IS A COMPLEX PROCESS, AND OUR FAILURE TO FULLY COMPLY COULD SUBJECT US TO SIGNIFICANT ENFORCEMENT ACTIONS.…
New disclosure of government customer procurement risk tied to appropriations and spending approvals, creating timing/volume sales impact from shutdowns.
DISRUPTIONS AT THE FDA AND OTHER GOVERNMENT AGENCIES OR NOTIFIED BODIES COULD PREVENT OUR PRODUCTS FROM BEING CLEARED, CERTIFIED, APPROVED, OR COMMERCIALIZED IN A TIMELY MANNER OR AT ALL, OR COULD…
Added OBBBA risk reducing Medicaid/ACA enrollment and demand. EU HTA now applicable (Jan 2025) vs. deferred to 2028, accelerating compliance burden.
CHANGES IN HEALTHCARE LEGISLATION AND POLICY MAY HAVE AN ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS. In the U.S., there have been, and continue to be, a number of…
New disclosure of competitive threats: competitors' faster technology integration, superior resources, recruitment competition, and academic/research institution competition. Escalates competitive risk beyond prior year's product-focused discussion.
RISKS RELATING TO OUR BUSINESS OUR COMMERCIAL LANDSCAPE IS HIGHLY COMPETITIVE, AND CUSTOMERS MAY CHOOSE OUR COMPETITORS’ PRODUCTS OR SERVICES OR MAY NOT ACCEPT ROBOTIC-ASSISTED MEDICAL PROCEDURES…
Regulatory landscape materially worsened: EU AI Act now in force (vs. pending); new state health-specific AI laws (Illinois, New York); Trump administration rescinding Biden AI safeguards and challenging state laws creates enforcement uncertainty and compliance complexity.
INCORPORATING ARTIFICIAL INTELLIGENCE TECHNOLOGIES INTO OUR PRODUCTS, SERVICES, AND OPERATIONS MAY RESULT IN LEGAL AND REGULATORY RISKS OR HAVE OTHER ADVERSE CONSEQUENCES TO OUR BUSINESS, FINANCIAL…
Expanded ESG compliance risk: added conflicting regulatory requirements, litigation/activism threats, and reputational harm as new material consequences beyond prior year's disclosure framework.
CLIMATE CHANGE, NATURAL DISASTERS, OR OTHER EVENTS BEYOND OUR CONTROL COULD DISRUPT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS. Natural disasters, terrorist activities, and other…
EU MDR regulatory landscape now explicitly described as "recently evolved and continues to undergo legislative changes" with December 2025 targeted revision proposal addressing structural issues and certification delays, escalating regulatory uncertainty and compliance burden.
OUR PRODUCTS ARE SUBJECT TO INTERNATIONAL REGULATORY PROCESSES AND APPROVAL OR CERTIFICATION REQUIREMENTS. IF WE DO NOT OBTAIN AND MAINTAIN THE NECESSARY REGULATORY REQUIREMENTS, WE WILL NOT BE ABLE…
Item 2.02 discloses Intuitive Surgical's Q2 2026 financial results via press release dated July 16, 2026. The filing reports quarterly revenue of $2.89 billion (19% growth), GAAP net income of $818 million ($2.29 per diluted share), and non-GAAP net income of $1.00 billion ($2.80 per diluted share), along with operational metrics including 16% procedure growth and 468 da Vinci system placements. This is a standard quarterly earnings release material to investors.
View raw filing on EDGAR →Taylor Patton's appointment as Chief Commercial and Marketing Officer is the principal disclosed action. While Henry L. Charlton's transition to a different senior role is also mentioned, the filing centers on the succession event—Patton succeeding Charlton in a C-suite commercial leadership position. This executive appointment at a major medical device company is material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →